Processa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial
A 0.5 mg daily dose of PCS12852 administered over 28 days in gastroparesis patients successfully improved…
A 0.5 mg daily dose of PCS12852 administered over 28 days in gastroparesis patients successfully improved…
The global metal fabrication service market companies analyzed in report are Helander Metal, Schaumburg Specialties LLC,…
Aesthetic medicine industry is estimated to grow 18.5% CAGR between 2023 and 2032 driven by rising…
Major automotive flooring market participants include DuPont de Nemours, Inc., Apache Mills, Inc., Hyosung Corporation, Conform…
Update Offers More Comprehensive Understanding of PaxMedica’s Focus, Process and Progress Tarrytown, NY, Dec. 14, 2022…
Huntsville, ONT., Dec. 14, 2022 (GLOBE NEWSWIRE) — Steadright Critical Minerals (CSE: SCM) (“Steadright” or the…
The announcement comes as development progresses on Hydrostor’s Willow Rock project in California (500MW – 4,000MWh)…
Mullen EV Charging Network Public DC Charging and Residential Offerings Powered By Loop Loop to offer…
Series B investment to propel adoption of Microsoft DaaS (Desktop-as-a-Service) management solutions for channel and enterprise…
MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody® sonelokimab in active psoriatic…